SG11201706767RA - Materials and methods for treatment of hemoglobinopathies - Google Patents

Materials and methods for treatment of hemoglobinopathies

Info

Publication number
SG11201706767RA
SG11201706767RA SG11201706767RA SG11201706767RA SG11201706767RA SG 11201706767R A SG11201706767R A SG 11201706767RA SG 11201706767R A SG11201706767R A SG 11201706767RA SG 11201706767R A SG11201706767R A SG 11201706767RA SG 11201706767R A SG11201706767R A SG 11201706767RA
Authority
SG
Singapore
Prior art keywords
hemoglobinopathies
treatment
materials
methods
Prior art date
Application number
SG11201706767RA
Inventor
Matthew Hebden Porteus
Thomas James Cradick
Gang Bao
Ciaran M Lee
Original Assignee
Crispr Therapeutics Ag
Georgia Tech Res Inst
Univ Rice William M
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crispr Therapeutics Ag, Georgia Tech Res Inst, Univ Rice William M filed Critical Crispr Therapeutics Ag
Publication of SG11201706767RA publication Critical patent/SG11201706767RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
SG11201706767RA 2015-02-23 2016-02-23 Materials and methods for treatment of hemoglobinopathies SG11201706767RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119754P 2015-02-23 2015-02-23
PCT/IB2016/000282 WO2016135558A2 (en) 2015-02-23 2016-02-23 Materials and methods for treatment of hemoglobinopathies

Publications (1)

Publication Number Publication Date
SG11201706767RA true SG11201706767RA (en) 2017-09-28

Family

ID=55795007

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201706767RA SG11201706767RA (en) 2015-02-23 2016-02-23 Materials and methods for treatment of hemoglobinopathies
SG11201706766WA SG11201706766WA (en) 2015-02-23 2016-02-23 Materials and methods for treatment of hemoglobinopathies

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201706766WA SG11201706766WA (en) 2015-02-23 2016-02-23 Materials and methods for treatment of hemoglobinopathies

Country Status (8)

Country Link
US (3) US10738305B2 (en)
EP (2) EP3262172A2 (en)
CN (2) CN107532182A (en)
AU (2) AU2016225179C1 (en)
BR (2) BR112017017812A2 (en)
CA (2) CA2977447A1 (en)
SG (2) SG11201706767RA (en)
WO (2) WO2016135558A2 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
SG11201508028QA (en) 2013-04-16 2015-10-29 Regeneron Pharma Targeted modification of rat genome
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
KR20230070319A (en) 2014-11-21 2023-05-22 리제너론 파마슈티칼스 인코포레이티드 METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
SG11201706767RA (en) 2015-02-23 2017-09-28 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
WO2016182959A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
WO2016201047A1 (en) 2015-06-09 2016-12-15 Editas Medicine, Inc. Crispr/cas-related methods and compositions for improving transplantation
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
US20190225955A1 (en) 2015-10-23 2019-07-25 President And Fellows Of Harvard College Evolved cas9 proteins for gene editing
EP3371306B8 (en) * 2015-11-04 2023-02-22 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
SG11201807859WA (en) * 2016-03-14 2018-10-30 Editas Medicine Inc Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
IL308426A (en) 2016-08-03 2024-01-01 Harvard College Adenosine nucleobase editors and uses thereof
CA3033327A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
WO2018071868A1 (en) 2016-10-14 2018-04-19 President And Fellows Of Harvard College Aav delivery of nucleobase editors
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
EP3573618B1 (en) * 2017-01-30 2023-08-16 The Children's Hospital of Philadelphia Compositions and methods for hemoglobin production
TW201839136A (en) * 2017-02-06 2018-11-01 瑞士商諾華公司 Compositions and methods for the treatment of hemoglobinopathies
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
CN110914310A (en) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 Cytosine to guanine base editor
WO2018170184A1 (en) 2017-03-14 2018-09-20 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
EP3622070A2 (en) 2017-05-10 2020-03-18 Editas Medicine, Inc. Crispr/rna-guided nuclease systems and methods
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US20200140896A1 (en) * 2017-06-30 2020-05-07 Novartis Ag Methods for the treatment of disease with gene editing systems
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
AU2018352592A1 (en) 2017-10-16 2020-06-04 Beam Therapeutics, Inc. Uses of adenosine base editors
MA50849A (en) * 2017-10-26 2020-09-02 Vertex Pharma SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
CN108103027B (en) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） Method for reprogramming blood cells with high efficiency and simultaneously realizing gene editing
EP3749768A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
AU2019230210A1 (en) * 2018-03-07 2020-10-01 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
WO2019178416A1 (en) * 2018-03-14 2019-09-19 Editas Medicine, Inc. Systems and methods for the treatment of hemoglobinopathies
EP3802826A1 (en) * 2018-05-24 2021-04-14 CRISPR Therapeutics AG Methods and compositions for efficient gene deletion
CN110863041A (en) * 2018-08-27 2020-03-06 深圳华大生命科学研究院 Mutant gene related to thalassemia and detection reagent and application thereof
KR20210108360A (en) * 2018-10-30 2021-09-02 크리스퍼 테라퓨틱스 아게 Compositions and methods for NHEJ-mediated genome editing
AU2020228377A1 (en) * 2019-02-26 2021-10-14 Percassist, Inc. Apparatus, systems, and methods for percutaneous pneumatic cardiac assistance
WO2020191246A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
MX2021013363A (en) * 2019-04-30 2021-11-18 Edigene Guangzhou Inc Method for predicting effectiveness of treatment of hemoglobinopathy.
CN111939271A (en) * 2019-04-30 2020-11-17 博雅辑因（北京）生物科技有限公司 Method for predicting treatment effectiveness of hemoglobinopathy
WO2020254872A2 (en) 2019-06-17 2020-12-24 Crispr Therapeutics Ag Methods and compositions for improved homology directed repair
CN110699381A (en) * 2019-09-17 2020-01-17 合肥瑞灵生物科技有限公司 Mediterranean anemia gene therapy vector construction method and application thereof
MX2022014008A (en) 2020-05-08 2023-02-09 Broad Inst Inc Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence.
WO2022147759A1 (en) * 2021-01-08 2022-07-14 Susheng Biotech (Hainan) Co., Ltd. Grna molecule targeting intron i or intron ii of hbb gene, synthetic method thereof, and method to correct types of hbb gene mutations
WO2023028469A2 (en) * 2021-08-23 2023-03-02 The Board Of Trustees Of The Leland Stanford Junior University Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells
CN113564248A (en) * 2021-09-26 2021-10-29 北京贝瑞和康生物技术有限公司 Method and kit for simultaneously detecting multiple mutations of HBA1/2, HBB and HBD gene sites
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (en) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Ring gap magnet system
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT728214E (en) 1993-11-09 2004-11-30 Ohio Med College CELL LINES ARE ABLE TO EXPRESS THE ADDITIONAL-ASSOCIATED VIRUS REPLICATION GENE
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
AU707866B2 (en) 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
FR2737730B1 (en) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc PROCESS FOR PURIFYING VIRUSES BY CHROMATOGRAPHY
US6143548A (en) 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
CA2230758A1 (en) 1995-09-08 1997-03-13 Genzyme Corporation Improved aav vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
ES2557997T3 (en) 1997-09-05 2016-02-01 Genzyme Corporation Methods for generating preparations of high titre AAV vectors without auxiliary virus
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
NZ583028A (en) 2000-10-27 2011-10-28 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
EP2334794B8 (en) 2008-09-15 2017-04-19 The Children's Medical Center Corporation Modulation of bcl11a for treatment of hemoglobinopathies
NZ630900A (en) * 2012-02-24 2016-10-28 Hutchinson Fred Cancer Res Compositions and methods for the treatment of hemoglobinopathies
DE102012007232B4 (en) 2012-04-07 2014-03-13 Susanne Weller Method for producing rotating electrical machines
DK3241902T3 (en) 2012-05-25 2018-05-07 Univ California METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
DK2890780T3 (en) 2012-08-29 2020-09-21 Sangamo Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING A GENETIC CONDITION
US20140085593A1 (en) 2012-09-21 2014-03-27 Shenzhen China Star Optoelectronics Technology Co., Ltd Mixture for Liquid Crystal Medium and Liquid Crystal Display Using the Same
DK2925864T3 (en) 2012-11-27 2019-02-11 Childrens Medical Ct Corp DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION
IL239344B1 (en) 2012-12-12 2024-02-01 Broad Inst Inc Engineering of systems, methods and optimized guide compositions for sequence manipulation
AU2014265331B2 (en) * 2013-05-15 2019-12-05 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
WO2014197748A2 (en) 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
EP3019595A4 (en) 2013-07-09 2016-11-30 Therapeutic uses of genome editing with crispr/cas systems
SI3019619T1 (en) 2013-07-11 2021-12-31 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use
US20150044772A1 (en) 2013-08-09 2015-02-12 Sage Labs, Inc. Crispr/cas system-based novel fusion protein and its applications in genome editing
CN105829536A (en) 2013-08-22 2016-08-03 纳幕尔杜邦公司 Methods for producing genetic modifications in a plant genome without incorporating a selectable transgene marker, and compositions thereof
JP2015092462A (en) 2013-09-30 2015-05-14 Tdk株式会社 Positive electrode and lithium ion secondary battery using the same
US10354746B2 (en) 2014-01-27 2019-07-16 Georgia Tech Research Corporation Methods and systems for identifying CRISPR/Cas off-target sites
JP6202701B2 (en) 2014-03-21 2017-09-27 株式会社日立国際電気 Substrate processing apparatus, semiconductor device manufacturing method, and program
EP3981876A1 (en) 2014-03-26 2022-04-13 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating sickle cell disease
CN106687601A (en) 2014-05-28 2017-05-17 株式会社图尔金 Method for sensitive detection of target DNA using target-specific nuclease
JP6197169B2 (en) 2014-09-29 2017-09-20 東芝メモリ株式会社 Manufacturing method of semiconductor device
WO2016089433A1 (en) 2014-12-03 2016-06-09 Agilent Technologies, Inc. Guide rna with chemical modifications
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
SG11201706767RA (en) 2015-02-23 2017-09-28 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
US20180112213A1 (en) 2015-03-25 2018-04-26 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
EP3280803B1 (en) 2015-04-06 2021-05-26 The Board of Trustees of the Leland Stanford Junior University Chemically modified guide rnas for crispr/cas-mediated gene regulation
EP3313989A4 (en) 2015-06-29 2018-12-05 Ionis Pharmaceuticals, Inc. Modified crispr rna and modified single crispr rna and uses thereof
EP3371306B8 (en) 2015-11-04 2023-02-22 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
MY192848A (en) 2015-12-28 2022-09-12 Intellia Therapeutics Inc Compositions and methods for the treatment of hemoglobinopathies
SG11201807859WA (en) 2016-03-14 2018-10-30 Editas Medicine Inc Crispr/cas-related methods and compositions for treating beta hemoglobinopathies
MX2018012729A (en) 2016-04-18 2019-07-04 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies.
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
GB2573664B (en) 2016-10-27 2022-09-28 Intima Bioscience Inc Viral methods of T cell therapy
MA50849A (en) 2017-10-26 2020-09-02 Vertex Pharma SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
EP3749768A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies

Also Published As

Publication number Publication date
CA2977447A1 (en) 2016-09-01
WO2016135558A3 (en) 2016-10-20
EP3262171A2 (en) 2018-01-03
US20180021413A1 (en) 2018-01-25
AU2016225178A1 (en) 2017-08-31
CA2977455A1 (en) 2019-09-01
CN107532182A (en) 2018-01-02
US20210317450A9 (en) 2021-10-14
WO2016135557A2 (en) 2016-09-01
AU2016225179A1 (en) 2017-08-31
EP3262172A2 (en) 2018-01-03
WO2016135557A3 (en) 2016-10-20
AU2016225178B2 (en) 2022-05-05
BR112017017812A2 (en) 2018-04-10
SG11201706766WA (en) 2017-09-28
AU2016225179B2 (en) 2022-05-05
US20180030438A1 (en) 2018-02-01
AU2016225178A9 (en) 2022-05-05
US20210009998A1 (en) 2021-01-14
US10738305B2 (en) 2020-08-11
CN107532168A (en) 2018-01-02
WO2016135558A2 (en) 2016-09-01
BR112017017810A2 (en) 2018-04-10
AU2016225179C1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
IL262416A (en) Materials and methods for treatment of hemoglobinopathies
SG11201706766WA (en) Materials and methods for treatment of hemoglobinopathies
HK1258205A1 (en) Compositions and methods for the treatment of hemoglobinopathies
HK1257955A1 (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
EP3371306B8 (en) Materials and methods for treatment of hemoglobinopathies
IL258931A (en) Therapeutic compounds and methods
HK1253049A1 (en) Glycan-interacting compounds and methods of use
GB2544180B (en) Cover means and method of use thereof
GB201514760D0 (en) Compounds and method of use
HK1249118A1 (en) Protoxin-ii variants and methods of use
HK1250476A1 (en) Protoxin-ii variants and methods of use
EP3134108A4 (en) Agents and methods of treatment
HK1258056A1 (en) Therapeutic compounds and methods of use thereof
GB2544343B (en) Receptacle and its method of manufacture
GB201511799D0 (en) Composition and methods of treatment
GB201605127D0 (en) Composition and methods of treatment
GB201417248D0 (en) Compostion and methods of treatment
GB2527046B (en) Device and method for the treatment of crops
ZA201802201B (en) Novel formulation and treatment methods
IL248847A0 (en) Dosage of dasotraline and method for treatment of adhd
GB201512139D0 (en) Methods of treatment
GB201503371D0 (en) Methods of screening and treatment
GB201500555D0 (en) Method and device for the treatment of diseases
GB201522615D0 (en) Methods of screening and treatment
GB201521083D0 (en) Compositions for treatment and methods thereof